Share This

Hot News @ 減重

 
Related Keyword:諾和諾德 , 減重 , 中國
Related Concept:諾和諾德減肥藥 , 禮來股價 , 減重版司美格魯肽正式 , 諾和諾德推減重 , 中國上市美股
 
美股前瞻 | 三大股指期貨齊跌,諾和諾德(NVO.US)減肥新藥臨床試驗大獲成功 @ 2025-01-26T
1. 1月24日(周五)美股盤前,美股三大股指期貨齊跌。截至發稿,道指期貨跌0.13%,標普500指數期貨跌0.15%,納指期貨跌0.15%。 2.
Keyword:諾和諾德
Concept:諾和諾德減肥藥 , 禮來股價
諾和諾德擬推減重藥2.0 執行長:有望在市場居領先地位 @ 2024-11-21T
在藥廠競相尋找成效比暢銷減重藥Wegovy及Mounjaro更好的產品之際,丹麥諾和諾德(Novo Nordisk) 正准備發表「下一代」減重藥物CagriSema的實驗數據,相信...
Keyword:減重 中國 諾和諾德
Concept:減重版司美格魯肽正式 , 諾和諾德推減重
《糖尿病》中國生物相似藥蓄勢待發,Ozempic 專利到期將引發市場激烈競爭- 生技投資第一站 @ 2024-11-20T
1. 中國成為GLP-1 受體促效劑的熱門市場2. Ozempic 在中國的專利期限為何較短? 3. 中國專利法修訂,但Ozempic 無法受惠4. 生物相似藥廠商挑戰Ozempic...
Keyword:減重 中國 諾和諾德
Concept:減重版司美格魯肽正式 , 中國上市美股
 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.